manometriin

Manometriin is a synthetic non‑steroidal anti‑inflammatory agent first described in 1985. The compound has a molecular formula of C19H23NO5, a melting point of 168 °C, and is formulated as a crystalline powder that is readily soluble in ethanol and weakly soluble in water.

Pharmacologically, manometriin selectively inhibits cyclo‑oxygenase‑2, thereby reducing the synthesis of prostaglandins that mediate pain and inflammation. The drug is absorbed rapidly when administered orally; peak plasma concentrations occur within 30 to 45 minutes. Manometriin is metabolized primarily in the liver by the cytochrome P450 2C19 system, and its metabolites are excreted mainly via the kidneys.

The medication is indicated for short‑term relief of acute joint and muscular pain, including that caused by overuse injuries and mild rheumatic conditions. It is available in 100 mg and 200 mg tablet formulations in Finland and Estonia, where it is marketed under several brand names. Clinical trials reported that a daily dose of 200 mg provided significant analgesic benefit without the gastrointestinal side effects commonly associated with other non‑steroidal agents.

Common adverse reactions include nausea, headache, and mild dizziness. Rare but serious complications may arise from hypersensitivity or hepatic dysfunction; therefore, patients with liver disease or a history of bleeding disorders are advised to use the drug under close medical supervision.

Manometriin was discovered by Dr. N. A. Salo in the pharmaceutical research unit of Helsinki University. The patent was granted in 1987, and the first clinical study was published in the Journal of Scandinavian Pharmacology in 1989. Subsequent research has examined the drug’s potential anti‑arthritic effects and its role in pain management protocols for athletes.